$ONCY News

Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer

Oncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment

Oncolytics Biotech Anticipates Reporting Final Results From Group 4 Of Its GOBLET Phase 1/2 Trial In Q4 For Pelareorep With Atezolizumab To Treat Squamous Cell Anal Carcinoma; To Receive Payment Under Grant From Pancreatic Cancer Action Network This Quarter

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

Oncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

Oncolytics Biotech's All Planned Facilities For Part A Of REO 033 Trial Activated, Multiple Participants Admitted

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

Oncolytics Biotech Announces Pelareorep Lowered Tumor Growth Compared To Control During Initial Treatment Period

ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC

HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5

Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Oncolytics Biotech Receives FDA's Fast Track Designation To Pelareorep In Combination With A Checkpoint Inhibitor Treat Squamous Cell Carcinoma Of Anal Canal

ONCY: Seeking Registration Pathway for Part B of REO 033 Trial